Pay-For-Delay Anti-Trust Lawsuit Against Pharma Company Dismissed
from the monopolies-galore dept
Last year, we wrote about the rise of pay-for-delay programs being run by big pharmaceutical firms to use patent lawsuits as a cover to pay off generic drug makers to prevent them from competing in the market. We were pretty disappointed that a part of health care reform that would have outlawed such deals got dropped, but figured that these still seemed like anticompetitive actions that the FTC could deal with.Well, that might not work either. Joe Mullin points out that one such lawsuit suggesting that some of these deals were anticompetitive has been tossed out. The specifics here are a bit more complex -- as the deal that the big pharma, Schering-Plough (now owned by Merck) worked out with two generic drug makers was technically structured as a "license deal" where Schering got to license drugs from those generic drugmakers -- even if it never really did so. It still provided some amount of "cover." Furthermore, the agreement not to introduce the generics in the market only occurred during the time when Schering's drug was still covered by the patent. So, really, there was some dispute as to whether or not the generic actually violated the patent or not -- but since the ruling was not about determining that fact, just whether the actions were anti-competitive, the judge concluded that there wasn't enough evidence of any anticompetitive behavior.
So, basically, the only reason this wasn't anticompetitive was because it all happened under a government-granted monopoly. Talk about ironic, right? Because there's a monopoly, the company doesn't get labeled a monopolist. Isn't the patent system great?
This ruling is unfortunate for a variety of reasons. You can see why generic drug makers agree to these deals: it's either go through an expensive fight to put a drug on the market, or get out of the lawsuit and get paid a ton of money for nothing. Not hard to make that decision. But the end result is anti-competitive, in that it allows big pharma firms to keep the prices jacked up very high on their drugs, much to the detriment of everyone else.
Thank you for reading this Techdirt post. With so many things competing for everyone’s attention these days, we really appreciate you giving us your time. We work hard every day to put quality content out there for our community.
Techdirt is one of the few remaining truly independent media outlets. We do not have a giant corporation behind us, and we rely heavily on our community to support us, in an age when advertisers are increasingly uninterested in sponsoring small, independent sites — especially a site like ours that is unwilling to pull punches in its reporting and analysis.
While other websites have resorted to paywalls, registration requirements, and increasingly annoying/intrusive advertising, we have always kept Techdirt open and available to anyone. But in order to continue doing so, we need your support. We offer a variety of ways for our readers to support us, from direct donations to special subscriptions and cool merchandise — and every little bit helps. Thank you.
–The Techdirt Team
Filed Under: anti-trust, pharma
Companies: schering-plough
Reader Comments
Subscribe: RSS
View by: Time | Thread
Our system is paid for by special interest groups like pharmaceutical corporations. No other reason.
[ link to this | view in thread ]
[ link to this | view in thread ]
[ link to this | view in thread ]
Re:
Yes, but wouldn't it be nice if they got a taste of their own medicine?
[ link to this | view in thread ]
Re:
[ link to this | view in thread ]
Regulatory Capture
[ link to this | view in thread ]